الرسائل الموجهة للمختصين الصحيين
الرسائل الموجهة للمختصين الصحيين
| المنتج | التاريخ | معلومات السلامة | المرفقات |
|---|---|---|---|
| Arava® -leflunomide | 2019-09-25 | Risk of serious birth defects when administered during pregnancy |
|
| Methotrexate "Ebewe” | 2019-09-21 | Recommendations to avoid potentially fatal dosing errors when using methotrexate “METHOTREXATE "EBEWE “ for autoimmune diseases |
|
| Roaccutne | 2019-09-11 | Roaccutne (isotretinoin): An update on neuropsychiatric disorders. |
|
| soliqua (lixisenatide /insuline glargin) soliqua | 2019-08-26 | (lixisenatide /insuline glargin): Important information on dosing. |
|
| Gilenya (fingolimod) | 2019-08-23 | Gilenya (fingolimod)): New contraindication in pregnant women and in women of childbearing potential not using effective contraception. |
|
| Advaquin ( levofloxacin) | 2019-08-13 | Advaquin ( levofloxacin): Risk of aortic aneurysm and dissection. |
|
| Darzalex (Daratumumab) | 2019-07-01 | Darzalex (Daratumumab): New identified risk of hepatitis B reactivation. |
|
| Lemtrada® Alemtuzumab | 2019-06-27 | Alemtuzumab (Lemtrada): New safety information. |
|
| Apixaban, Edoxaban, Dabigatran and Rivaroxaban | 2019-06-12 | Direct Healthcare Professional Communication (DHPC) for the Direct Oral Anticoagulants (DOACs) Apixaban, Edoxaban, Dabigatran and Rivaroxaban. |
|
| blinatumomab | 2019-05-07 | Blincyto (pembrolizumab): Risk of Medication Errors and Benzyl alcohol toxicity. |
|